| BAYLOR COLLEGE OF MEDICINE Patent applications |
| Patent application number | Title | Published |
|---|
| 20120041297 | REAL-TIME MAGNETIC DIPOLE DETECTION AND TRACKING - A system for detecting a position and/or orientation of a magnetic dipole includes a first detector and a second detector, separate and spaced apart from the first detector. Each of the detectors includes three or more magnetic field sensors to detect a magnetic field generated by the magnetic dipole. The system has applications, for example, in image-guided surgery and/or therapy. | 02-16-2012 |
| 20120040456 | METHODS OF GENE THERAPY USING NUCLEIC ACID SEQUENCES FOR ATP-BINDING CASSETTE TRANSPORTER - The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention. | 02-16-2012 |
| 20120021405 | Single Chain Antibody for the Detection of Noroviruses - The present invention concerns compositions and methods for detecting Norovirus or Norovirus particles. In particular, the present invention encompasses antibodies for detecting Norovirus or Norovirus particles, including, for example, monoclonal antibodies that have broad specificity of binding to various genogroups of norovirus. | 01-26-2012 |
| 20110263014 | Cleavage of Nanog by Caspases Mediates the Differentiation of Embryonic Stem Cells - The present invention is based on the discovery that a caspase specifically cleaves the transcription factor, Nanog, leading to the initiation of cellular differentiation of embryonic stem (ES) cells. The present invention includes a method of inhibiting the cleavage of Nanog, thereby maintaining the pluripotency of an ES cell or preventing the differentiation of an ES cell. The present invention further provides compositions and methods for inhibiting caspase expression, activity, and/or stability. | 10-27-2011 |
| 20110212076 | Viral Therapeutic - The invention provides a method of inhibiting viral infection of a mammalian cell, said method comprising reducing or inhibiting ps20 polypeptide expressed by said cell. Suitably ps20 is inhibited by contacting said cell with an antibody capable of binding to ps20 polypeptide. Suitably said antibody is ps20 neutralising antibody. The invention also provides antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding ps20 polypeptide, or antisense ps20 polynucleotide for use as a medicament for viral infection. The invention also provides a method of identifying an agent for inhibiting a viral infection, comprising determining level of ps20 expression in first and second samples, the first contacted with test agent; and comparing the level of ps20 expression in said first and second samples; wherein lower level of ps20 expression in said first sample relative to said second sample identifies test agent as an agent for inhibiting a viral infection. | 09-01-2011 |
| 20110197628 | CRYOAGGREGATE FILTRATION FOR THE TREATMENT OF CARDIOMYOPATHY AND OTHER AUTOIMMUNE DISEASES - Various embodiments of the present invention disclose processes and systems for the off-line in-vitro purification of plasma harvested from a patient. In an embodiment of a process, in a first step cellular components are capable of being eliminated by membrane plasma separation at temperatures sufficiently high to avoid formation of a cryoaggregates, and in a second step the resulting plasma solution is cooled to a temperature that allows the formation of cryoaggragated molecules, but no formation of a cryogel. | 08-18-2011 |
| 20110189263 | PEPTIDES THAT TARGET DORSAL ROOT GANGLION NEURONS - The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy. | 08-04-2011 |
| 20110178555 | BONE COMPRESSION DEVICE - The invention relates to bone compression devices and bone compression systems, and in particular, to bone compression devices and systems for use in connection with vertebrae. The bone compression devices and bone compression systems are disposed, or installed, along at least one bone to maintain the at least one bone in a desired spatial relationship. Broadly, the invention is directed to a bone compression device for placing in communication with at least one bone having a bone radius of curvature, the bone compression device comprising a plate having a pre-formed shape, a deformed shape, and at least one elastic shape therebetween, the pre-formed shape having a pre-formed radius of curvature less than the bone radius of curvature, the deformed shape having a deformed radius of curvature greater than the bone radius of curvature, and at least one of the at least one elastic shapes having an elastic radius of curvature that substantially corresponds to the bone radius of curvature. The invention is also directed to a bone compression system wherein the plate includes a string attached to each end of the plate and a tensioner for facilitating the movement of the plate from the pre-formed shape to the at least one elastic shape. Methods of maintaining a bone in a spatial relationship and methods of contouring the bone compression devices are also disclosed. | 07-21-2011 |
| 20110158915 | NANOSHELLS WITH TARGETED ENHANCEMENT OF MAGNETIC AND OPTICAL IMAGING AND PHOTOTHERMAL THERAPEUTIC RESPONSE - A particle and a method of manufacturing a particle that includes a complex, a paramagnetic entity, and a silica layer that encapsulates the paramagnetic entity and the complex. The dielectric layer of the particle encapsulates the complex and the paramagnetic entity such that at least a portion of an outer surface of the complex is covered by the paramagnetic entity. In addition, the particle may or may not include a fluorescent entity encapsulated within the dielectric layer. Also, the particle may or may not include a targeting entity covalently bonded to the silica layer. | 06-30-2011 |
| 20110020786 | PEPTIDE DENDRIMERS: AFFINITY REAGENTS FOR BINDING NOROVIRUSES - Noroviruses are recognized as the most common cause of outbreaks of acute gastroenteritis in humans. Therefore, the present invention relates to peptides or dendrimers that bind Noroviruses and the methods for identifying and synthesizing these peptides. It also relates to the detection of Noroviruses using said peptides or dendrimers formed by them. | 01-27-2011 |
| 20100331281 | PHOSPHOLIPID COMPOSITIONS AND USES THEREOF - We have discovered that phospholipids diundecanoyl (C11:0-C11:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids and structurally related lipids. Also featured are methods of treating metabolic disorders and inflammatory bowel disease, lowering blood glucose levels, and increasing LRH-1 receptor activity in a subject by administration of these lipids. | 12-30-2010 |
| 20100291123 | T Cell Receptor CDR3 Sequences and Methods for Detection - The present invention relates generally to the field of treating autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA) and others. Methods of treating and monitoring an autoimmune disease by utilizing T-cell receptors peptides are disclosed. Nucleic acid and peptide sequences of T-cell receptors found in a population of MS patients are also disclosed. | 11-18-2010 |
| 20100273862 | Phosphatases which activate map kinase pathways - The present invention provides novel JNK activating phosphatase polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing JNK activating phosphatase polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with JNK activating phosphatase polypeptides. | 10-28-2010 |
| 20100266623 | SYNTHETIC, SELF ADJUVANTING VACCINES - The present invention relates generally to the field of immunotherapy, and more particularly to immunomedicaments in the form of lipopeptides which induce an antibody response to drugs of dependence, and uses thereof in the treatment and prevention of drug addiction. | 10-21-2010 |
| 20100241241 | REMOTE ACTUATED VALVE IMPLANT - Valve implant systems positionable within a flow passage, the systems having an inlet, an outlet, and a remotely activatable valve between the inlet and outlet, with the valves being operable to provide intermittent occlusion of the flow path. A remote field is applied to provide thermal or magnetic activation of the valves. | 09-23-2010 |
| 20100239548 | Isolation and Identification of T Cells - The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention further directed to the diagnosis of T associated diseases. | 09-23-2010 |
| 20100216119 | Diagnostic Methods for HIV Infection - The invention relates to a method of aiding the diagnosis of a human immunodeficiency virus infection in a subject, said method comprising (i) providing a sample from the subject (ii) determining the level of ps20 in said sample (iii) comparing the level of ps20 of (ii) with the level of ps20 in an uninfected reference sample, wherein a higher level of ps20 in the sample from the subject compared to the uninfected reference sample indicates an increased likelihood of human immunodeficiency virus infection in said subject. The invention also relates to methods for assessing susceptibility of a subject to human immunodeficiency virus infection. Most suitably the ps20 level is determined via binding by an anti-ps20 antibody such as the 107 antibody. The invention also relates to kits for use in said methods. | 08-26-2010 |
| 20100203067 | METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS - Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment. | 08-12-2010 |
| 20100197610 | FRUCTOSE 1, 6 BISPHOSPHATE - A NOVEL ANTICONVULSANT DRUG - The present invention concerns methods and compositions for preventing one or more epileptic seizures in an individual by delivering fructose-1,6-bisphosphate to the individual. In certain cases, an additional therapy for epilepsy is provided to the individual. | 08-05-2010 |
| 20100183546 | Method for Increasing CD8+ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis - The present invention relates generally to the field of immunology and development of autologous vaccines. More specifically, the present invention is concerned with a method of treating autoimmune disease Multiple Sclerosis (MS) by means of immunizing patients with autologous CD8 | 07-22-2010 |
| 20100143255 | FIG4 GENE MUTATIONS IN NEURODEGENERATION - The present invention relates to neuropathy, in particular to mutations in the FI G4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states. | 06-10-2010 |
| 20100112610 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 05-06-2010 |
| 20100112082 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 05-06-2010 |
| 20090269753 | GENOTYPING FOR SRC-1 PREDICTS FOR BONE LOSS - Osteoporosis is a common skeletal disease characterized by loss of bone mineral density (BMD) and increased risk of fracture. Osteoporosis most commonly occurs in postmenopausal women due to estrogen deficiency. We identified 3 genetic variants in steroid receptor coactivator 1 (SRC-1) that are significantly associated with a decrease in BMD in women. We characterized a functional variant in exon 18 of SRC-1 that is associated with increased loss of bone mineral density in women who received tamoxifen for treatment or prevention of breast cancer. In vitro experiments show that this variant decreases estrogen receptor alpha response (ER-alpha) to hormone, suggesting an attenuated response to endogenous and exogenous hormones in the bone of these women, and therefore a need for additional bone protective measures. | 10-29-2009 |
| 20090256069 | APPARATUS FOR DESORPTION AND IONIZATION OF ANALYTES - This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules. Most specifically, this invention relates to the sample probe geometry, sample probe composition, and sample probe surface chemistries that enable the selective capture and desorption of analytes, including intact macromolecules, directly from the probe surface into the gas (vapor) phase without added chemical matrix. | 10-15-2009 |
| 20090219607 | METHOD AND APPARATUS FOR ENHANCED RESOLUTION MICROSCOPY OF LIVING BIOLOGICAL NANOSTRUCTURES - The present invention is a method and apparatus that utilizes an inertia-free diffraction mechanism to control both phase and rotation of the standing wave pattern that results in super-resolution at unparalleled imaging speeds. In some embodiments of the present inventions, AODs are utilized to control period, phase, and rotation of the SW pattern in contrast to the commonly used mechano-optical principles. This allows 2D (and 3D) super-resolution imagining at high stability and speed not limited by mechanical constraints. The present invention can be utilized, for example, for real time observations of dynamic processes in living cells. | 09-03-2009 |
| 20090215147 | Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy - The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity. | 08-27-2009 |
| 20090202108 | ASSAYING AND IMAGING SYSTEM IDENTIFYING TRAITS OF BIOLOGICAL SPECIMENS - A method of system is provided for assaying specimens. In connection with such system or method, plural multi-pixel target images of a field of view are obtained at different corresponding points in time over a given sample period. A background image is obtained using a plural set of the plural target images. For a range of points in time, the background image is removed from the target images to produce corresponding background-removed target images. Analysis is performed using at least a portion of the corresponding background-removed target images to identify visible features of the specimens. A holding structure is provided to hold a set of discrete specimen containers. A positioning mechanism is provided to position a plural subset of the containers to place the moving specimens within the plural subset of the containers within a field of view of the camera. | 08-13-2009 |
| 20090200341 | Adjustable-Volume Liquid Dispensing Pump - An adjustable-volume liquid dispenser is disclosed. In one embodiment, an adjustable-volume liquid dispenser includes a spout and a plunger secured to the spout. The dispenser further includes a plunger lock moveable lengthwise along the plunger. The plunger lock is securable to the plunger at a plurality of positions on the plunger to adjust a volume of liquid to be dispensed. The dispenser also includes a spring in contact with the plunger. In addition, the dispenser includes a chamber comprising an interior for containing liquid. The plunger is slidably arranged with the chamber. A portion of the plunger is disposed within the chamber. Moreover, the dispenser includes a chamber cap secured to the chamber, and a valve disposed within the chamber. The dispenser also includes a shaft secured to the chamber. | 08-13-2009 |
| 20090170748 | Plasmid mediated supplementation for treating chronically ill subjects - The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and methods are useful for treating anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the animal tissue specific constitutive expression is achieved. | 07-02-2009 |
| 20090157122 | BONE COMPRESSION DEVICE - The invention relates to bone compression devices and bone compression systems, and in particular, to bone compression devices and systems for use in connection with vertebrae. The bone compression devices and bone compression systems are disposed, or installed, along at least one bone to maintain the at least one bone in a desired spatial relationship. Broadly, the invention is directed to a bone compression device for placing in communication with at least one bone having a bone radius of curvature, the bone compression device comprising a plate having a pre-formed shape, a deformed shape, and at least one elastic shape therebetween, the pre-formed shape having a preformed radius of curvature less than the bone radius of curvature, the deformed shape having a deformed radius of curvature greater than the bone radius of curvature, and at least one of the at least one elastic shapes having an elastic radius of curvature that substantially corresponds to the bone radius of curvature. The invention is also directed to a bone compression system wherein the plate includes a string attached to each end of the plate and a tensioner for facilitating the movement of the plate from the pre-formed shape to the at least one elastic shape. Methods of maintaining a bone in a spatial relationship and methods of contouring the bone compression devices are also disclosed. | 06-18-2009 |
| 20090131475 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS - The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B—C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example. | 05-21-2009 |
| 20090123501 | INHIBITION OF THE SH2-DOMAIN CONTAINING PROTEIN TYR-PHOSPHATASE, SHP-1, TO ENHANCE VACCINES - The invention describes the use of dendritic cell vaccines, wherein SHP-1 expression or activity is modulated in the dendritic cell. In particular, the invention provides dendritic cells (DC) transduced with an SHP1-shRNA adenovirus, or dominant negative (dn-SHP-1) or constitutively active (ca-SHP-1), and pulsed with an antigen. The methods and compositions of the invention are used for the prevention and/or treatment of cancers, other cell proliferation diseases and conditions, diseases caused by a pathogen, or autoimmune disorders. | 05-14-2009 |
| 20090075928 | G-QUARTET OLIGONUCLEOTIDES THAT TARGET HYPOXIA-INDUCIBLE FACTOR 1-a (HIF1a ) - The present invention concerns particular G-quartet oligonucleotides that are employed for the treatment and/or prevention of cancer. In specific cases, the G-quartet oligonucleotides inhibit HIF-1α. | 03-19-2009 |
| 20090062620 | Methods for Estimating the Metabolic Cost of Walking - Methods for determining the metabolic cost for walking are disclosed. In one embodiment, a method for determining metabolic cost per unit time of a walk by an individual is disclosed. The method includes providing a body length of the individual. The method also includes measuring a walking speed of the individual. The metabolic cost per unit time is determined by adding a basal metabolic rate and a metabolic constant for walking to the result of a metabolic coefficient for walking multiplied by the walking speed (squared) and such squared speed divided by the body length of the individual. | 03-05-2009 |
| 20090042205 | FLUORESCENCE DETECTION OF DNA BREAKS USING MOLECULAR OSCILLATORS - A method to detect DNA breaks includes providing a mixture of fluorescence energy transfer molecular oscillators and a DNA sample. The FET oscillator is a synthetic oligonucleotide that has a topoisomerase recognition sequence, a fluorescence donor and a fluorescence acceptor. The synthetic oligonucleotide is bound to a type I topoisomerase capable of binding to the topoisomerase recognition sequence. The mixture is irradiated at a wavelength of the fluorescence donor, and the emission is measured. Another variant of the disclosure is a probe for detecting DNA breaks utilizing a synthetic oligonucleotide comprising a topoisomerase recognition sequence, a fluorescence donor, and a nonradiative fluorescence quencher. Yet another variant of the disclosure is a probe for detecting DNA breaks utilizing a synthetic oligonucleotide comprising a topoisomerase recognition sequence, a fluorescence donor, and a fluorescence acceptor. The mixture is irradiated at a wavelength of the fluorescence donor; and the emission is measured. A method to detect DNA breaks may use these probes in a manner similar to that of the FET oscillator. The FET oscillators and probes are capable of being prepared in a kit formulation. | 02-12-2009 |
| 20090029930 | Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter - The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention. | 01-29-2009 |
| 20080311140 | Antigen specific immunosuppression by dendritic cell therapy - The invention includes genetically modified dendritic cells expressing at least two immunosuppressive molecules. The genetically modified dendritic cells have the ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases. | 12-18-2008 |
| 20080226609 | Transplantation of Glial Restricted Precursor-Derived Astrocytes for Promotion of Axon Growth - Provided herein are compositions and methods for the treatment of central nervous system (CNS) lesions comprising administration of glial restricted precursor (GRP) derived astrocytes (GDAs). | 09-18-2008 |
| 20080207543 | MODIFIED PITUITARY GLAND DEVELOPMENT IN OFFSPRING FROM EXPECTANT MOTHER ANIMALS TREATED WITH GROWTH HORMONE RELEASING HORMONE THERAPY - The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the FI offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age. Consistent with their augmented growth, plasma IGF-I concentration of the FI progeny was increased significantly. The pituitary gland of the offspring was significantly heavier, and contained an increased number of somatotropes (cells producing GH) and lactotrophs (prolactin-secreting cells), and is indicative of an alteration in cell lineages. These unique findings demonstrate that enhanced GHRH expression in pregnant dams can result in intergenerational growth promotion, by altering development of the pituitary gland in the offspring. | 08-28-2008 |
